BiAqua, DSM enter partnership for strain and process development of BiAqua Ferritin

DSM BioSolutions, Royal DSM's microbial fermentation contract manufacturing business, and BiAqua B.V., an innovator in delivering bio-based solutions for serious water contamination issues, today announced that they have entered into an agreement for strain development, process development and production of "BiAqua Ferritin" for BiAqua's core technology to address bio-fouling and arsenic contamination in the water sector.  

DSM has successfully started strain and process development of BiAqua Ferritin at its process development facility in Delft, The Netherlands and will shortly commence with scale-up and manufacturing of BiAqua Ferritin at its microbial fermentation biotech facility located in Capua, Italy. The BiAqua Ferritin will be used for BiAqua water contamination studies in collaboration with water companies and consumers worldwide to reduce bacterial and arsenic contamination. DSM's Capua facility is uniquely equipped for the production of biologically active compounds produced via microbial fermentation and has extensive experience in both bacterial and fungal fermentation.

Nityen Lal, Managing Director of BiAqua, stated, "DSM has assembled a first class team to help us drastically optimize the cost of production on the basis of their expertise, proprietary tools and technology. This should enable BiAqua to offer an affordable bio-based solution to the market in the short term."

Villaume Kal, Vice-President of DSM BioSolutions stated, "We are delighted to work with BiAqua, an innovative and progressive company developing bio-based solutions to worldwide water contamination issues. Our technology, operational excellence and outstanding regulatory compliance record allows us to serve this important customer and to develop and manufacture their Ferritin product."


DSM BioSolutions


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Sartorius BIA Separations and Exopharm Sign Joint Research Agreement to Develop Integrated Technology